Neurocrine Biosciences (NBIX) Leases (2019 - 2025)
Historic Leases for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2025 value amounting to $455.4 million.
- Neurocrine Biosciences' Leases fell 1060.07% to $455.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $455.4 million, marking a year-over-year decrease of 1060.07%. This contributed to the annual value of $455.4 million for FY2025, which is 1060.07% down from last year.
- Neurocrine Biosciences' Leases amounted to $455.4 million in Q4 2025, which was down 1060.07% from $468.9 million recorded in Q3 2025.
- In the past 5 years, Neurocrine Biosciences' Leases registered a high of $509.4 million during Q4 2024, and its lowest value of $80.8 million during Q3 2023.
- Moreover, its 4-year median value for Leases was $257.3 million (2024), whereas its average is $264.1 million.
- In the last 5 years, Neurocrine Biosciences' Leases skyrocketed by 22085.31% in 2024 and then tumbled by 1060.07% in 2025.
- Neurocrine Biosciences' Leases (Quarter) stood at $97.9 million in 2021, then surged by 103.27% to $199.0 million in 2023, then skyrocketed by 155.98% to $509.4 million in 2024, then fell by 10.6% to $455.4 million in 2025.
- Its Leases was $455.4 million in Q4 2025, compared to $468.9 million in Q3 2025 and $492.3 million in Q2 2025.